發送短信 : A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)

  _  _      ___      _  __     ___      ______  
 | \| ||   / _ \\   | |/ //   / _ \\   /_   _// 
 |  ' ||  / //\ \\  | ' //   / //\ \\    | ||   
 | .  || |  ___  || | . \\  |  ___  ||  _| ||   
 |_|\_|| |_||  |_|| |_|\_\\ |_||  |_|| /__//    
 `-` -`  `-`   `-`  `-` --` `-`   `-`  `--`